NDLI: The targeted therapy revolution in neuroendocrine tumors: in search of biomarkers for patient selection and response evaluation

Content Provider	Springer Nature Link
Author	Dosso, Sara Grande, Enrique Barriuso, Jorge Castella, Daniel Tabernero, Josep Capdevila, Jaume
Copyright Year	2013
Abstract	The molecular events of tumorigenesis in neuroendocrine tumors are poorly understood. Understanding of the molecular alterations will lead to the identification of molecular markers, providing new targets for therapeutics. The purpose of this review was to critically analyze the genetic abnormalities in neuroendocrine tumors, with the aim of identifying biomarkers that indicate a response to agents developed against these targets and to serve as an understanding for the combinations of different active compounds. Human epidermal growth factor receptor 1/2 (EGFR and HER2), vascular endothelial growth factor receptors, hepatocyte growth factor receptor (c-Met), platelet-derived growth factor receptor, insulin-like growth factor, phosphatidylinositol 3-kinase–Akt–mammalian target of rapamycin pathway, and heat shock proteins are all interesting candidate biomarkers with involvement in carcinogenesis and tumor evolution of several neoplasms, including neuroendocrine tumors. Some of them have already been evaluated both as targets and also as biomarkers in clinical trials conducted in advanced neuroendocrine tumor settings, and others should encourage further investigations into innovative therapeutic opportunities.
Starting Page	465
Ending Page	477
Page Count	13
File Format	PDF
ISSN	01677659
Journal	Cancer and Metastasis Reviews
Volume Number	32
Issue Number	3-4
e-ISSN	15737233
Language	English
Publisher	Springer US
Publisher Date	2013-04-16
Publisher Place	Boston
Access Restriction	One Nation One Subscription (ONOS)
Subject Keyword	Neuroendocrine tumor Biomarker Target therapy Tyrosine kinase inhibitor Cancer Research Oncology Biomedicine general
Content Type	Text
Resource Type	Article
Subject	Cancer Research Oncology

Sl.	Authority	Responsibilities	Communication Details
1	Ministry of Education (GoI), Department of Higher Education	Sanctioning Authority	https://www.education.gov.in/ict-initiatives
2	Indian Institute of Technology Kharagpur	Host Institute of the Project: The host institute of the project is responsible for providing infrastructure support and hosting the project	https://www.iitkgp.ac.in
3	National Digital Library of India Office, Indian Institute of Technology Kharagpur	The administrative and infrastructural headquarters of the project	Dr. B. Sutradhar bsutra@ndl.gov.in
4	Project PI / Joint PI	Principal Investigator and Joint Principal Investigators of the project	Dr. B. Sutradhar bsutra@ndl.gov.in Prof. Saswat Chakrabarti will be added soon
5	Website/Portal (Helpdesk)	Queries regarding NDLI and its services	support@ndl.gov.in
6	Contents and Copyright Issues	Queries related to content curation and copyright issues	content@ndl.gov.in
7	National Digital Library of India Club (NDLI Club)	Queries related to NDLI Club formation, support, user awareness program, seminar/symposium, collaboration, social media, promotion, and outreach	clubsupport@ndl.gov.in
8	Digital Preservation Centre (DPC)	Assistance with digitizing and archiving copyright-free printed books	dpc@ndl.gov.in
9	IDR Setup or Support	Queries related to establishment and support of Institutional Digital Repository (IDR) and IDR workshops	idr@ndl.gov.in

The targeted therapy revolution in neuroendocrine tumors: in search of biomarkers for patient selection and response evaluation.

Therapy innovations: tyrosine kinase inhibitors for the treatment of pancreatic neuroendocrine tumors

Innovations therapy: mammalian target of rapamycin (mTOR) inhibitors for the treatment of neuroendocrine tumors

Molecular biology of neuroendocrine tumors: from pathways to biomarkers and targets

Current treatments and future potential of surufatinib in neuroendocrine tumors (NETs)

Clinical Progress of Anti-Angiogenic Targeted Therapy and Combination Therapy for Gastric Cancer

Current knowledge on diagnosis and staging of neuroendocrine tumors

Insulin-like growth factor-1 receptor (IGF-1R) as a biomarker for resistance to the tyrosine kinase inhibitor gefitinib in non-small cell lung cancer

The search for the primary tumor in metastasized gastroenteropancreatic neuroendocrine neoplasm

The targeted therapy revolution in neuroendocrine tumors: in search of biomarkers for patient selection and response evaluation

Similar Documents

The targeted therapy revolution in neuroendocrine tumors: in search of biomarkers for patient selection and response evaluation.

Therapy innovations: tyrosine kinase inhibitors for the treatment of pancreatic neuroendocrine tumors

Innovations therapy: mammalian target of rapamycin (mTOR) inhibitors for the treatment of neuroendocrine tumors

Molecular biology of neuroendocrine tumors: from pathways to biomarkers and targets

Current treatments and future potential of surufatinib in neuroendocrine tumors (NETs)

Clinical Progress of Anti-Angiogenic Targeted Therapy and Combination Therapy for Gastric Cancer

Current knowledge on diagnosis and staging of neuroendocrine tumors

Insulin-like growth factor-1 receptor (IGF-1R) as a biomarker for resistance to the tyrosine kinase inhibitor gefitinib in non-small cell lung cancer

The search for the primary tumor in metastasized gastroenteropancreatic neuroendocrine neoplasm

The targeted therapy revolution in neuroendocrine tumors: in search of biomarkers for patient selection and response evaluation